Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study

Authors

James L Januzzi, Harvard Medical School
Alaa Mabrouk Salem Omar, Icahn School of Medicine at Mount Sinai
Yuxi Liu, Harvard Medical School
Sean Murphy, Harvard Medical School
Javed Butler, University of Mississippi
G Michael Felker, Duke University School of Medicine
Iliana L Piña, Thomas Jefferson UniversityFollow
Jonathan Ward, Novartis Pharmaceuticals Corporation
Scott Solomon, Harvard Medical School
Johanna Contreras, Icahn School of Medicine at Mount Sinai

Document Type

Article

Publication Date

11-22-2022

Comments

This article is the author’s final published version in Circulation, Volume 146, Issue 21, November 2022, Pages 1638-1640.

The published version is available at https://doi.org/10.1161/CIRCULATIONAHA.122.061693. Copyright © Januzzi et al.

Recommended Citation

Januzzi, James L; Omar, Alaa Mabrouk Salem; Liu, Yuxi; Murphy, Sean; Butler, Javed; Felker, G Michael; Piña, Iliana L; Ward, Jonathan; Solomon, Scott; and Contreras, Johanna, "Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study" (2022). Division of Cardiology Faculty Papers. Paper 110.
https://jdc.jefferson.edu/cardiologyfp/110

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Language

English

PubMed ID

36183276